Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.

Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J.

Oncotarget. 2016 Aug 16;7(33):53350-53361. doi: 10.18632/oncotarget.10804.

2.

Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway.

Fabris L, Berton S, Citron F, D'Andrea S, Segatto I, Nicoloso MS, Massarut S, Armenia J, Zafarana G, Rossi S, Ivan C, Perin T, Vaidya JS, Avanzo M, Roncadin M, Schiappacassi M, Bristow RG, Calin G, Baldassarre G, Belletti B.

Oncogene. 2016 Sep 15;35(37):4914-26. doi: 10.1038/onc.2016.23. Epub 2016 Feb 15.

3.

Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases.

Xu Q, Malecka KL, Fink L, Jordan EJ, Duffy E, Kolander S, Peterson JR, Dunbrack RL Jr.

Sci Signal. 2015 Dec 1;8(405):rs13. doi: 10.1126/scisignal.aaa6711.

4.

Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells.

Wang T, Yuan J, Zhang J, Tian R, Ji W, Zhou Y, Yang Y, Song W, Zhang F, Niu R.

Oncotarget. 2015 Oct 13;6(31):30975-92. doi: 10.18632/oncotarget.5199.

5.

IGFBP2 potentiates nuclear EGFR-STAT3 signaling.

Chua CY, Liu Y, Granberg KJ, Hu L, Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller GN, Nykter M, Cavenee WK, Zhang W.

Oncogene. 2016 Feb 11;35(6):738-47. doi: 10.1038/onc.2015.131. Epub 2015 Apr 20.

7.

Inferring protein modulation from gene expression data using conditional mutual information.

Giorgi FM, Lopez G, Woo JH, Bisikirska B, Califano A, Bansal M.

PLoS One. 2014 Oct 14;9(10):e109569. doi: 10.1371/journal.pone.0109569. eCollection 2014. Erratum in: PLoS One. 2016;11(9):e0163402.

8.

Monoclonal Antibodies Specific for STAT3β Reveal Its Contribution to Constitutive STAT3 Phosphorylation in Breast Cancer.

Bharadwaj U, Kasembeli MM, Eckols TK, Kolosov M, Lang P, Christensen K, Edwards DP, Tweardy DJ.

Cancers (Basel). 2014 Sep 29;6(4):2012-34. doi: 10.3390/cancers6042012.

9.

Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells.

Sangar V, Funk CC, Kusebauch U, Campbell DS, Moritz RL, Price ND.

Mol Cell Proteomics. 2014 Oct;13(10):2618-31. doi: 10.1074/mcp.M114.040428. Epub 2014 Jul 5.

10.

Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours.

Zhang X, Blaskovich MA, Forinash KD, Sebti SM.

Br J Cancer. 2014 Aug 26;111(5):894-902. doi: 10.1038/bjc.2014.349. Epub 2014 Jul 1.

11.

Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Furcht CM, Buonato JM, Skuli N, Mathew LK, Muñoz Rojas AR, Simon MC, Lazzara MJ.

J Cell Sci. 2014 Aug 15;127(Pt 16):3555-67. doi: 10.1242/jcs.150862. Epub 2014 Jun 20.

12.

STAT3 and epithelial-mesenchymal transitions in carcinomas.

Wendt MK, Balanis N, Carlin CR, Schiemann WP.

JAKSTAT. 2014 Jan 1;3(1):e28975. doi: 10.4161/jkst.28975. Epub 2014 Apr 29. Review.

13.

Genetic Interactions of STAT3 and Anticancer Drug Development.

Fang B.

Cancers (Basel). 2014 Mar 6;6(1):494-525. doi: 10.3390/cancers6010494.

14.

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA.

Cancer Cell. 2013 Oct 14;24(4):438-49. doi: 10.1016/j.ccr.2013.09.004.

15.

STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor.

Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J, Stark GR.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16975-80. doi: 10.1073/pnas.1315862110. Epub 2013 Sep 30.

16.

Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.

Urlam MK, Pireddu R, Ge Y, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti SM, Lawrence NJ.

Medchemcomm. 2013 Jun;4(6):932-941.

17.

HIC1 interacts with and modulates the activity of STAT3.

Lin YM, Wang CM, Jeng JC, Leprince D, Shih HM.

Cell Cycle. 2013 Jul 15;12(14):2266-76. doi: 10.4161/cc.25365.

18.

Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling.

Huang SS, Clarke DC, Gosline SJ, Labadorf A, Chouinard CR, Gordon W, Lauffenburger DA, Fraenkel E.

PLoS Comput Biol. 2013;9(2):e1002887. doi: 10.1371/journal.pcbi.1002887. Epub 2013 Feb 7.

19.

A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, Bast RC Jr, Robertson FM, McMurray JS.

J Exp Ther Oncol. 2012;10(2):155-62.

20.

A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation.

Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, Guida WC, Lawrence NJ, Sebti SM.

Cancer Res. 2013 Mar 15;73(6):1922-33. doi: 10.1158/0008-5472.CAN-12-3175. Epub 2013 Jan 15.

Supplemental Content

Support Center